Business Description
Avalo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05338F3064
Description
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 202.16 | |||||
| Equity-to-Asset | -0.82 | |||||
| Debt-to-Equity | -0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -9.88 | |||||
| Beneish M-Score | -5.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -71.3 | |||||
| 3-Year EBITDA Growth Rate | 62.9 | |||||
| 3-Year EPS without NRI Growth Rate | 60.7 | |||||
| 3-Year FCF Growth Rate | 60.3 | |||||
| 3-Year Book Growth Rate | -21.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.86 | |||||
| 9-Day RSI | 49.43 | |||||
| 14-Day RSI | 48.87 | |||||
| 6-1 Month Momentum % | -3.82 | |||||
| 12-1 Month Momentum % | -97.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.52 | |||||
| Quick Ratio | 0.52 | |||||
| Cash Ratio | 0.51 | |||||
| Days Inventory | 10.6 | |||||
| Days Sales Outstanding | 9.57 | |||||
| Days Payable | 945.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 14.5 | |||||
| Shareholder Yield % | -1072.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.9 | |||||
| Operating Margin % | -1371.03 | |||||
| Net Margin % | -9853.72 | |||||
| FCF Margin % | -1855.31 | |||||
| ROA % | -304.7 | |||||
| ROIC % | -31.71 | |||||
| ROC (Joel Greenblatt) % | -1155.28 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.92 | |||||
| EV-to-EBIT | 3.53 | |||||
| EV-to-EBITDA | 3.55 | |||||
| EV-to-Revenue | -59.19 | |||||
| EV-to-Forward-Revenue | 0.3 | |||||
| EV-to-FCF | 3.2 | |||||
| Earnings Yield (Greenblatt) % | 28.33 | |||||
| FCF Yield % | -217.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avalo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.338 | ||
| EPS (TTM) (€) | -294.496 | ||
| Beta | 0 | ||
| Volatility % | 489.44 | ||
| 14-Day RSI | 48.87 | ||
| 14-Day ATR (€) | 0.710348 | ||
| 20-Day SMA (€) | 10.464 | ||
| 12-1 Month Momentum % | -97.6 | ||
| 52-Week Range (€) | 0.0355 - 964.799992 | ||
| Shares Outstanding (Mil) | 1.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avalo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avalo Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Avalo Therapeutics Inc Frequently Asked Questions
What is Avalo Therapeutics Inc(STU:C6K0)'s stock price today?
The current price of STU:C6K0 is €10.70. The 52 week high of STU:C6K0 is €964.80 and 52 week low is €0.04.
When is next earnings date of Avalo Therapeutics Inc(STU:C6K0)?
The next earnings date of Avalo Therapeutics Inc(STU:C6K0) is 2024-08-02 Est..
Does Avalo Therapeutics Inc(STU:C6K0) pay dividends? If so, how much?
Avalo Therapeutics Inc(STU:C6K0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers